CURRICULUM VITAE DR. DHEERAJ MOHANIA, Ph.D. Tel ......2018/03/16 · Dr. Dheeraj Mohania,...

Dr. Dheeraj Mohania, Scientist-I (Dr. R. P. Centre), All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi-110029, India 1

CURRICULUM VITAE

DR. DHEERAJ MOHANIA, Ph.D. Scientist-I (National Eye Bank)

Dr. R. P. Centre for Ophthalmic Sciences (Dr. R. P. Centre) All India Institute of Medical Sciences (AIIMS)

Ansari Nagar, New Delhi-110029, India Tel: +91-9582299697; +91-9899367051

Tel: 011-26593060 E-mail: [email protected]; [email protected]

Area of interest: Cancer biology and translational research Work Experience: Total 7 years (February 2010-October 2016): worked as Associate Scientist Consultant and Assistant Professor (GRIPMER) in Department of Research, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi-110060, India under the guidance of Prof. Nirmal Kumar Ganguly (Ex. Director General, Indian Council of Medical Research (ICMR), New Delhi, India). Educational Accomplishments: Doctorate of Philosophy- (Biochemistry) (2005- 2011) Animal Biochemistry Division, National Dairy Research Institute (N.D.R.I.), Karnal, Haryana, India. Master of Science (Biochemistry) 2002-2004 Department of Biochemistry, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi- 110062, India Bachelor of Science (Microbiology) 1999-2002 Ram Lal Anand College, South Campus, University of Delhi, New Delhi, India Teaching Experience of M.Sc. and Ph.D Students 10 years

M.Sc. Thesis Guided 16 TOTAL PROJECTS (9) PROJECTS SANCTIONED FOR EXTRAMURAL FUNDING (3) PROJECTS SANCTIONED FOR INTRAMURAL FUNDING (6)

mailto:[email protected]

mailto:[email protected]


DST Project as Principal Investigator (PI) entitled “Clinical Significance of Cancer Stem Cell Markers In Different Grades of grades of Astrocytomas” (YSS/2014/00008) from Department of Science and Technology (DST-SERB), New Delhi 2014. (27.26 lakh).

DBT project as Co-Investigator (PI) entitled “Biomarkers to enhance the accuracy and precision of prediction of short-term and long-term outcome after spontaneous intracerebral haemorrhage: a prospective cohort study” (1.256 Crores).

DBT project as Co-Investigator (PI) entitled “Deciphering the genetic aetiology of stroke in Indians using whole exome sequencing using an established and already externally fully funded multicentric Indian stroke biobank” (2.039 Crores). NUMBER OF RESEARCH PROJECTS ON HAND: 9 1. Clinical Significance of Cancer Stem Cell Markers in Different Grades of Astrocytomas (Funded by Department of Science and Technology (DST) project as Principal Investigator- (27.26 lakh). The present study is designed to determine functional contribution of various cancer stem cells (CSCs), MGMT methylation status and drug response (TMZ) in the presence of MGMT inhibitor on CSCs in different grades of astrocytoma. The outcome of the study will offer an identification and characterization of cancer stem cells (CSCs) and MGMT methylation status and effect of TMZ (with or without MGMT inhibitor) on CSCs and their correlation in various grades of astrocytoma that may facilitate the development of novel strategies for better prognosis, patient survival, patient outcome, clinico-histopathological correlation and treatment of advanced as well as metastatic brain cancer. In addition, molecular characterization of cancer stem cells in low and high grade glioma is one immense value as low grade glioma are mostly well differentiated and show better progression while high grade glioma such as glioblastoma are poorly differentiated and exhibit worst progression will further help in understanding might mechanisms to provide new insights in identifying specific biomarkers for cancer diagnosis, prognostic evaluation and developing modern therapies in future. Therefore, the present proposal has been undertaken to (1) study the prognostic/predictive value of various cancer stem cell markers in different grades of astrocytoma and (2) evaluate the effect of different MGMT inhibitors for sensitizing chemo-resistant glioma stem cells (GSCs) for temozolomide (TMZ) in different grades of Astrocytoma. 2. Deciphering the genetic aetiology of stroke in Indians using whole exome sequencing using an established and already externally fully funded multicentric Indian stroke biobank (Funded by Department of Biotechnology (DBT) project as Co-Investigator- (2.039 Crores). Stroke is the biggest cause of disability, second cause of dementia and the third largest cause of mortality in the world. The WHO estimates that by 2050 around 80% of the world’s burden of stroke will rest between India and China. There are few therapeutic options in stroke with the acute treatment having to be administered within 3 hours and virtually unavailable in India. Understanding the genetics of stroke, offers our best way of


developing therapeutics interventions. The USA, UK, Germany and Australia have led the world in genetically characterizing their stroke populations for their benefit. Countries in the Middle East are beginning to do the same. We are on track to complete the required number of samples of 1500 cases and 2500 controls within the coming ~12 months. It is expected that this work will build considerable capacity in India in the ability to analyse large highly phenotyped repositories to world class standards. A large body of evidence have contributed suggests a genetic contribution to stroke onset in both Caucasians and South Asians. Dissecting out the underlying genetic mechanisms for stroke may help us to understand the reasons why the South Asian population seem particularly at risk from stroke and help us to decipher the different mechanisms by which stroke arises in the Indian population. Perhaps more importantly, knowing that there currently exist few treatments for acute stroke, comprising mainly of aspirin (which needs to be prescribed to ~80 patients to benefit one individual) and clot busting drugs (which are virtually unavailable in the Indian subcontinent) a clear need exists to identify new drugs targets. Understanding the genetics of stroke likely provides us with one of our best hopes for developing population specific drugs to combat this devastating condition. Therefore, the present proposal has been undertaken to answer these key questions, (1) what are the genetic loci that are involved in common ischaemic and haemorrhagic stroke? (2) How do these loci compare with the genome studies undertaken in populations of European descent? (3) Are these loci suitable as novel drug targets?

3. Biomarkers to enhance the accuracy and precision of prediction of short-term and long term outcome after spontaneous intracerebral haemorrhage: a prospective cohort study. (Funded by Department of Biotechnology (DBT) project as Co-Investigator (1.256 Crores). Spontaneous intracerebral haemorrhage (sICH) accounts for at least 20 to 30% of stroke cases in Indian hospitals whereas 15% in western countries. In general, the prognosis of sICH is poor both in short-term and long-term. There are several established predictors for the outcomes of sICH includes age, location and size of hematoma, midline shift, level of consciousness at admission, intraventricular extension, and admission blood pressure: include clinical and neuroimaging. Several biomarkers such as CRP level, S100B, serum glial fibrillary acidic protein, troponin, change in leukocyte count, copeptin levels are reported to predict the clinical outcome after ICH. Small studies have suggested that biomarkers may be independent predictors of re-bleeding and prognosis in patients with sICH; but none of them are established. No study, large enough to have power to examine all clinical, neuroimaging and laboratory parameters, have been done. This multi-centric study is designed to fill this gap. Specifically, the study aims to examine whether the biomarkers can significantly add to the predictive accuracy of prognosis of ICH. In this project, we will examine whether any of the biomarkers CRP level, serum glial fibrillary acidic protein, troponin, change in leukocyte count, S100B and copeptin levels are independent predictors of the neurological outcomes in patients with primary intracerebral haemorrhage, and whether any of them (singly or in combination) improve the predictive accuracy of clinically important outcomes.


4. Correlation of biomolecular levels of Progranulin and its association with NF-kB/β-catenin signaling pathway in the patients with intervertebral lumbar disc prolapse with the preoperative MRI and clinical outcomes after microlumbar discectomy. [Funded by Research Development program (RDP), Sir Ganga Ram Hospital, New Delhi] Intervertebral disc (IVD) degeneration is a common degenerative disease, yet much is unknown about the mechanisms during its pathogenesis. Recent reports suggested that the association of progranulin (PGRN) with human IVD degeneration, and suggested that PGRN may serve as a potential molecular target for prevention and treatment of disc degenerative diseases. Since mechanisms by which IVD degeneration ensues are largely unknown, there are no therapeutic targets that effectively prevent and treat the disease. However, growth factors, cytokines and matrix-degrading enzymes are strongly implicated in initiating and aggravating IVD degeneration. Thus, a molecular understanding of interplays among these molecules will provide invaluable information toward the search for novel therapeutic targets for IVD degeneration. Therefore, the present study has been designed with following objectives to correlate the biomolecular levels of progranulin (PGRN) and its association with NF-κB/β-catenin signaling pathway in the patients with intervertebral lumbar disc prolapse with the preoperative MRI and clinical outcomes after microlumbar discectomy. (1) To evaluate the expression of progranulin (PGRN) in serum and intervertebral lumbar disc in patients with intervertebral lumbar disc prolapse; (2) To study the transcriptional profiling of candidate genes involved in NF-κB/β-catenin signaling pathway in patients with intervertebral lumbar disc prolapse; (3) To explore the clinical correlation of progranulin (PGRN) and candidate genes involved in NF-κB/β-catenin signaling pathway with preoperative MRI and clinical outcomes after microlumbar discectomy in patients with intervertebral lumbar disc prolapse. 5. To explore the crosstalk of SIRT-1 with IL23/Th17/STAT3/Wnt signaling pathway and their clinical correlation with disease outcome of newly diagnosed patients with Rheumatoid arthritis. [Funded by Research Development program (RDP), Sir Ganga Ram Hospital, New Delhi] Rheumatoid arthritis (RA) is a chronic debilitating disease of the joints characterized by leukocyte infiltration, hyper-proliferation of synovial cells and bone destruction. The exact causes of RA are unknown. However, it is well accepted that a combination of factors, including abnormal autoimmune response, genetic susceptibility, and some environmental or biologic triggers, such as viral infection or hormonal changes, is involved in RA development. There is lack of information available on the role of SIRT-1, cAMP and their molecular crosstalk with IL-23/Th17/STAT3/Wnt pathway in newly diagnosed RA patients. This work will explore the links of between sirtuin-1 [class III histone deacetylase (HDAC)], cAMP, candidate genes involved in IL-23/Th17/STAT3/Wnt pathway, and disease progression in newly diagnosed patients with RA. However, direct evidence for the role of SIRT-1, cAMP and their molecular crosstalk with IL-23/Th17/STAT3/Wnt pathway in newly diagnosed RA patients. Therefore, this proposal will explore the links of between sirtuin-1 [class III histone deacetylase (HDAC)], cAMP, candidate genes involved in IL-23/Th17/STAT3/Wnt pathway, and disease progression in newly diagnosed patients with


RA. To the best of our knowledge, the direct link between SIRT-1, cAMP and their molecular crosstalk with IL-23/Th17/STAT3/Wnt pathway and their correlation with clinical outcome in newly diagnosed RA patients have not been reported so far. Therefore, the present is designed to study the following objectives (1) To evaluate the expression of sirtuin-1 (SIRT-1) and its association with cAMP levels in serum and peripheral blood mononuclear cells (PBMC) in newly diagnosed patients with Rheumatoid arthritis; (2) To study the transcriptional profiling of candidate genes involved in IL-23/Th17 pathway in newly diagnosed patients with Rheumatoid arthritis; (3) To assess the expression analysis of key genes involved in STAT3/Wnt pathway and associated transcription factors in newly diagnosed patients with Rheumatoid arthritis; (4) To explore the clinical correlation of SIRT1, cAMP, IL-23/Th17 pathway, STAT3/Wnt pathway and zinc finger transcription factors with disease outcome in newly diagnosed patients with Rheumatoid arthritis. 6. To explore the impact of packed red blood cell (PRBCs) on transfusion related immunomodulation (TRIM) in critically ill ICU admitted patients. [Funded by Research Development program (RDP), Sir Ganga Ram Hospital, New Delhi] Emerging evidences from variety of sources indicate that allogenic RBC transfusion often produces a myriad of immunologic derangements, from suppressive to stimulatory. Although it is often necessary and life-saving in clinical practice, transfusion of packed red blood cells (PRBCs) alters the immune system, producing both proinflammatory and anti-inflammatory responses. Based on the strong pre-clinical evidence of PRBCs transfusion for immunosuppression in variety of disease conditions, the present proposal is designed to explore the impact of PRBCs transfusion on various pro-inflammatory cytokines, markers of endothelial activation and transcriptional status of key enzymes involved in kynurenine metabolic pathway and their correlation in critically ill ICU patients. This study will therefore comprehensively investigate the impact of PRBCs transfusion and provide insight into the consequences of PRBCs interactions pre and post-transfusion, which may lead to development of safer blood components and improved understanding of transfusion-induced immunosuppression and tolerance. Furthermore, this new knowledge regarding the involvement of kynurenine pathway metabolism in stored PRBCs, pre and post-transfusion of PRBCs in critically ill ICU patients is, however, as yet unknown. Therefore, the present study is designed with the following objectives: (1) To assess the status of Th1/Th2/Th17 cytokines in stored PRBCs and their impact in critically ill ICU patients before and after PRBC transfusion; (2) To assess the markers of endothelial activation in stored PRBCs and their impact in critically ill ICU patients before and after PRBC transfusion; (3) To assess the transcriptional profiling of key enzymes involved in immunosuppression via tryptophan catabolism through kynurenine pathway in stored PRBCs and their impact before and after PRBC transfusion in critically ill ICU patients; (4) To explore the clinical correlation of Th1/Th2/Th17 cytokines, markers of endothelial activation and immunosuppression via candidate genes involved in tryptophan catabolism in critically ill ICU patients.


7. Towards understanding the mechanisms of immunomodulation, gut maturation and their correlation with clinical outcome in very low birth weight (VLBW) infants. [Funded by Research Development program (RDP), Sir Ganga Ram Hospital, New Delhi] There is paucity in the literature about the molecular mechanisms of immunomodulation and gut maturation in very low birth weight (VLBW) infants. The molecular mechanisms of immunomodulation and gut maturation that alter primary colonization and secondary persistence of more or less pathogenic microbes within the developing microbiota are not well understood, particularly in very low birth weight (VLBW) infants. Therefore, an approach towards understanding the molecular mechanism of immunomodulation and gut maturation is the key to future. To date, it remains largely unknown the molecular mechanism of immunomodulation and gut maturation in VLBW infants that will aid in understanding the incidence of NEC, sepsis and overall mortality. Hence, the present study is designed to investigate the molecular mechanism of immunomodulation and gut maturation in VLBW infants with the following objectives are designed to (1) investigate the comparative evaluation of inflammatory cytokines in blood and exfoliated colonocytes from fecal samples from VLBW infants; (2) evaluate the status of immunoglobulin receptors, gut cellular markers in developing newborn gut using exfoliated colonocytes isolated from fecal samples of VLBW infants; (3) evaluate the transcriptional status of indoleamine 2,3-dioxygenase (IDO) and its association with markers of sepsis in exfoliated colonocytes from fecal samples from VLBW infants; (4) assess the clinical correlation of immunoglobulin receptors, gut cellular markers, inflammatory cytokines with necrotizing enterocolitis (NEC), sepsis, overall mortality. 8. Optimization of collection, isolation, expansion, characterization and cryopreservation of bone-marrow derived mesenchymal stem cells. [Funded by Research Development program (RDP), Sir Ganga Ram Hospital, New Delhi] Mesenchymal stem cells (MSCs), also termed multipotent mesenchymal stromal cells, are phenotypically and functionally heterogeneous cell population. MSCs have the ability to self-renew and differentiate into cells of mesodermal lineages such as bone, cartilage and adipose tissue as well as cells of embryonic lineages. This is a single site, prospective study, for isolation, characterization and expansion of MSCs from patients undergoing bone marrow aspiration. Expansion and characterization of MSCs will be done on normal bone marrow samples at the Department of Research, Sir Ganga Ram Hospital, New Delhi. The immunomodulatory properties of MSCs may be exploited for therapeutic purpose in addition to the regenerative capacity that will be effective in renal transplant patients where it can replace the use of induction therapy reagents including rATG and anti-IL2 antibody. The study aims at establishing the protocols for in vitro expansion of MSCs derived from bone marrow for therapeutic intervention in live donor renal transplant (LDRT) patients at our hospital. Furthermore, this study will demonstrate the feasibility of in vitro using MSCs as an induction therapy that may reduce the adverse effect caused by induction therapy such as rATG /Basiliximab including cytokine release in LDRT recipients. It may also later help in lowering the dose of immunosuppressants and thus


decreasing the chances of opportunistic infections in these patients as well as reducing the several toxic effects of the immunosuppressants. 9. Exploring the transcriptional analysis of key enzymes involved in kynurenine pathway and their correlation with clinical outcome in newly diagnosed patients with Chronic Myeloid Leukemia. [Funded by Research Development program (RDP), Sir Ganga Ram Hospital, New Delhi] There is strong evidence that suppression of antitumor immune responses in precancerous lesions and established cancers by tryptophan catabolism promotes tumor growth, which would make tryptophan catabolism an attractive target for therapeutic intervention in CML patients. This may be due to tumor escape from immune recognition by downregulation of target antigen or antigen-processing machinery, by down modulation of recognition and stimulation molecules or because of the production of inhibitory cytokines. The kynurenine pathway of tryptophan catabolism is a strong candidate for the missing link of immunosuppressive microenvironment in CML patients because enzymes that gate the first step of the conversion of tryptophan to kynurenine are influenced by stress, glucocorticoids and the immune system. Based on the strong pre-clinical evidence for immunosuppression in other types of cancers, the present proposal is designed to explore the transcriptional status of key enzymes involved in kynurenine metabolic pathway and their correlation to clinical abnormalities in CML patients. This study will therefore comprehensively investigate the extent of the involvement of the kynurenine pathway in mediating the effects of tyrosine kinase inhibitors and immune function on core clinical and biological abnormalities in CML, and define the key biomarkers associated with the kynurenine pathway in CML. Furthermore, this study will also explore the status of tryptophan and kynurenine in the sera of CML patients. AWARDS AND MERITS: GATE qualified 2004. Junior Research Fellowship awarded by the Indian Council of Agricultural Research (Government of India) during the Doctorate’s degree (2005-2006). Senior Research Fellowship awarded by the Indian Council of Agricultural Research (Government of India) during the Doctorate’s degree (2006-2007). Rajiv Gandhi National Fellowship awarded by the University Grant Commission (U.G.C.) during the Doctorate’s degree (2007-2011). Travel Grant awarded by scientific committee of the 3rd International Probiotic Conference (IPC 2008), Hotel Bellevue, High Tatras, Slovakia, and Europe. Travel Grant awarded by scientific committee of the 5th Conference for the Asia Federation of Societies for Lactic Acid Bacteria (AFSLAB), Singapore Society for Microbiology & Biotechnology, Singapore. Travel Grant awarded by Scientific Committee of the International conference on Probiotic and Prebiotics 2013, Kosice, Slovakia. International travel grant awarded by Indian Council of Medical Research, New Delhi, India for attending International conference on Probiotic and Prebiotics 2013, Kosice, Slovakia.


International travel grant awarded by Department of Science and Technology (DST), India for presenting research paper on cancer stem cells and glioma at RTTC, Shanghai, China. Young Scientist Awarded by Department of Science and Technology (DST-SERB), New Delhi, Government of India in 2015.

PUBLICATIONS

RESEARCH ARTICLES 1. Uemura J, Nagpal R, Zerbinati N, Singh B, Marcellino M, Mohania D, Marotta F, He F, Ayala A, Kasugai Y, Catanzaro R. 2017. Effect of VBC-1814/7J, a poly-phytocompound, on a non-infectious model of pharyngitis. Exp Ther Med. 2017 Jun;13(6):3075-3080. 2. Catanzaro R, Zerbinati N, Solimene U, Marcellino M, Mohania D, Italia A, Ayala A and Marotta F. 2016. Beneficial effect of refined red palm oil on lipid peroxidation and monocyte tissue factor in HCV-related liver disease: a randomized controlled study. Hepatobiliary Pancreat Dis Int. 5(2):165-172. 3. Naito Y, Kaji Y, Catanzaro R, Sollano J, Mohania D, Marcellino M, Milazzo M, Makida Y. Onotera M. Sawada T, Marotta F. 2015. Efficacy of a bicarbonate-based cytoprotective phytocompound in mild non-esophagitis reflux disease (NERD): A DOUBLE-BLIND, RCT STUDY. Experimental and Therapeutic Medicine (Accepted). 4. Marotta F, Purshanmugama N, Mohania D, Zerbinati N. 2015. Marine Nutraceutical promotes fibroblasts proliferation, migration, and collagen synthesis in damaged cells: An in vitro study revisiting the concept of “CELL THERAPY”. Experimental and Therapeutic Medicine (Accepted). 5. Mohania D, Kansal VK, Kruzliak P, Kumari A. 2014. Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum modulates the formation of aberrant crypt foci, mucin depleted foci and cell proliferation on 1, 2-dimethylhydrazine induced colorectal carcinogenesis in Wistar rats. Rejuvenation Research 17(4):325-33. 6. Mohania D, Kansal VK, Sagwal R, Kruzliak P. 2014. Probiotic Lavk2 Dahi Improves Lipid Profiles in Hypercholesterolemic Rats. Adv Dairy Res 2: 113. doi: 10.4172/2329-888X.1000113. 7. Zerbinati N, Marotta F, Nagpal R, Singh B, Mohania D, Milazzo M, Sapienza C, Italia A, Tomella C, Catanzaro R. 2014. Protective effect of a sturgeon egg homogenate marine compound on arterial ultrastructure in spontaneous hypertensive rats. Rejuvenation Research 17(2):176-9. 8. Mohania D, Kansal VK, Shah D. 2013. Probiotic Dahi containing Lactobacillus acidophilus and Lactobacillus plantarum suppresses DMH induced preneoplastic lesions in early colorectal carcinogenesis in Wistar Rats. American Journal of Cancer Biology 1(2):1-14. 9. Mohania D, Kansal VK, Sagwal R, Batish VK, Grover S, Dilip S. 2013. Anticarcinogenic effect of probiotic Dahi and piroxicam on DMH-induced colorectal carcinogenesis in Wistar rats. American Journal of Cancer Therapy and Pharmacology 1(1): 8-24. 10. Mohania D, Kansal VK, Nagpal R, Yamashiro Y, Marotta F. 2013. Suppression of diet- induced hypercholesterolemia by probiotic Dahi containing Lactobacillus acidophilus and Lactobacillus plantarum. International journal of Probiotics and Prebiotics 8 (2/3):75-84.


11. Mohania D, Kansal VK, Shah D, Nagpal R, Kumar M, Gautam SK, Singh B, Behare PV. 2013. Therapeutic potential of probiotic Dahi on plasma, aortic and hepatic lipid profile of hypercholesterolemic rats. Journal of Cardiovascular pharmacology and Therapeutics 18(5):490-7. 12. Mohania D, Kansal VK, Kumar M, Nagpal R, Yamashiro Y, Marotta F. 2013. Modulation of expression of Programmed Death-1 by administration of probiotic Dahi in DMH-induced colorectal carcinogenesis in rats. Acta Biomedica 84(2):102-9. 13. Kapil D, Giri SK, Kumar A, Khuttan A, Yadav A, Mandhan RP, Kumar M, Mohania D, Kumar S, Singh L, Kumar V, Gautam SK. 2011. Studies of various microbial contaminants during culturing of amniotic fluid derived cells in buffalo (Bubalus bubalis). International Journal of Animal Biotechnology, 1(1):111-116. 14. Behare PV, Singh R, Tomar SK, Nagpal R, Kumar M, Mohania D. 2010. Effect of exopolysaccharide producing strains of Streptococcus thermophilus on technological attributes of fat-free lassi. Journal of Dairy Science, 93(7): 2874-2879 [Cited by 4]. 15. Kumar M, Mohania D, Poddar D, Behare PV, Nagpal R. 2009. A Probiotic Fermented milk Prepared by Mixed Culture Combination Reduces Pathogen Shedding and Alleviates Disease Signs in Rats Challenged with pathogens. International Journal of Prebiotics and Probiotics, 4(3): 211-218[Cited by 5]. REVIEW ARTICLES 1. Misra S, Kumar A, Kumar P, Yadav AK, Mohania D, Pandit AK, Prasad K, Vibha D. 2017. Blood-based protein biomarkers for stroke differentiation: A systematic review. Proteomics Clin Appl. 11(9-10). 2. Choudhury S, Mohania D, Dinand V, Taneja V, Agrahari S, Mangla K, Jain K, Ganguly NK. 2013. Applications of flow cytometry in healthcare: An update, The Ganga Ram Journal, 3:158-169. 3. Singh S, Mal G, Bharti D, Mohania D, Kuma M, Gautam SK, Marotta F, Yadav H, Nagpal R 2013. Probiotics in Female Reproductive Health: Paradigms, Prospects and Challenges. Current Women’s Health Reviews 9: 239-248. 4. Yadav M, Jain S, Menon S, Mohania D, Parkash O, Marotta F, Minelli E, Gebrt CJK and Yadav H. 2012. Milk, milk products and disease free health: an updated overview. Critical reviews in Food Science & Nutrition, 52(4): 321-333 [Cited by 8]. 5. Ganguly NK, Choudhury S, Mohania D, Jain K, Chug, Nair J. 2011. Research initiatives at Sir Ganga Ram Hospital. The Ganga Ram Journal, 1(2): 78-84. 6. Kumar M, Kumar A, Nagpal R, Mohania D, Behare P, Verma V, Kumar P, Poddar D, Aggarwal PK, Henry CJK, Jain S and Yadav H. 2010. Cancer Preventive attributes of probiotics: An update.International Journal of Food Sciences and Nutrition, 61(5): 473-497 [Cited by 38]. 7. Kumar M, Behare PV, Mohania D, Arora S, Kaur A and Nagpal R. 2009. Health promoting probiotic functional foods: potential and prospects. Agro Food Industry Hi-Tech, 20(3):29- 34 [Cited by 2]. 8 Kumar M, Mohania D, Kumar A, Nagpal R, Behare PV, Aggarwal PK, Yadav M, Marotta F, Jain S and Yadav H. 2009. Metabolomics: An emerging tool for nutrition research. Current topics in nutraceutical Research 7(2): 97-105 [Cited by 2].


9. Kumar M, Nagpal R, Mohania D, Poddar D and Aggarwal PK 2009. Genetically modified foods: present scenario and future prospects. Beverage & Food World 36: 38-40. 10. Mohania D, Nagpal R, Kumar M, Bhardwaj A, Yadav M, Jain S, Marotta F, Singh V, Parkash O and Yadav H. 2008. Molecular approaches for identification and characterization of lactic acid bacteria. Journal of Digestive Diseases 9(4); 190-198 [Cited by 46]. Research Papers presented in International Conference 1. Mohania D, Bhandari N, Chandel S, Tripathi D, Grover C. 2017. Inflammasomes and colorectal cancer: New insights in probiotics. Annals of Oncology, Volume 28, Issue suppl_3, 1 June 2017, mdx261.250, https://doi.org/10.1093/annonc/mdx261.250. 2. Misra S, Kumar A, Kumar P, Mohania D, Prasad K, Vibha D. 2017. To determine the diagnostic performance characteristics of blood based protein biomarkers for the differentiation of stroke using high-throughput proteomics approach: A study protocol. May 2017. Conference: 3rd European Stroke Organisation Conference, At Prague, Czech Republic. 3. Misra S, Kumar A, Kumar P, Yadav A K, Mohania D, Sagar R, Vibha D, Prasad K. 2017. Blood based protein biomarkers to distinguish ischemic from hemorrhagic stroke: A systematic review. Journal of the Neurological Sciences. Volume 381, Supplement, 15 October 2017, 6 4. Misra S, Kumar A, Ram S, Agrawal C, Kaul B, Gorthi S, Dabla S, Mohania D, Vibha D, Prasad K. 2017. Role of copeptin as a biomarker for predicting outcome after spontaneous intracerebral hemorrhage: a prospective cohort study. October 2017. DOI10.1016/j.jns.2017.08.1752. Journal of the Neurological Sciences. Volume 381, Supplement, 15 October 2017, Page 622 5. Misra S, Kumar A, Vibha D, Mohania D, Sagar R, Prasad K. 2017. Role of blood leukocyte count as a biomarker for predicting outcome after spontaneous intracerebral hemorrhage: A prospective cohort study. May 2017. Conference: 3rd European Stroke Organisation Conference, At Prague, Czech Republic 6. Mohania D, Y. Shokeen Y, Jauhri M, Aggarwal S. 2016. Association of kynurenine, tryptophan and key enzymes involved in kynurenine pathway of tryptophan catabolism with Imatinib duration in patients with chronic myeloid leukemia. Annals of Oncology, Volume 27, Issue suppl_9, 1 December 2016, mdw586.007, https://doi.org/10.1093/annonc/mdw586.007 7. Mohania D, Acharya R, Kalra S K, Jain K, Tripathi D. 2016. Clinical correlation of cancer stem cells in low and high grade glioma of North Indian population. Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 341P, https://doi.org/10.1093/annonc/mdw367.19 8. Bhargava V, Digvijay K, Mohania D, Rana D. S. 2016. Comparison of Tacrolimus with Everolimus or Mycophenolate Mofetil or Steroid Regimen and Their Association with Tryptophan Metabolism : A Pilot Study. November 2016. American Society of Nephrology (ASN), Volume: J Am Soc Nephrol 27:2016

https://doi.org/10.1093/annonc/mdx261.250

https://doi.org/10.1093/annonc/mdw586.007


9. Mohania D, Roy S, Acharya R, Bhalla S, Choudhury S, Jain S. 2014. Cancer stem cell and gliomas. International forum of regional and targeted therapy (RTTC 2014), 14-16th November 2014, Shanghai, China. 10. Choudhury S, Agrahari S, Gupta M, Mangal K, Mohania D, Kumaran V, Mehta N, Nundy S. 2013. Circulating regulatory T cells as markers of immune response to tolerance in Living Donor Liver Transplant recipients. XXIII Annual Conference of Indian Association of Surgical Gastroenterology, Hyatt Regency Kolkata, Kolkata; 3-6 October 2013. 11. Choudhury S, Jain D, Mohania D, Mirza R, Dhawan S, Mehta N, Nayak NC, Nundy S. 2013. Association of Octamer binding transcription factor 4 and Glycipan 3 in viral-induced and non-viral-induced hepatocellular carcinoma, IX DAE-BRNS Life Sciences Symposium (LSS-2013): Current advances in Immuno Biological and Cancer, Bhabha Atomic Energy Research Centre, Mumbai; 28-30th November 2013. 12. Mohania D and Kansal V.K. 2009. Presented a research paper in 5th Conference of the Asian Federation of Societies for Lactic Acid bacteria, 1st Jul and 4th July 2009, National University of Singapore (NUS), Singapore entitled“Effect of probiotic Dahi containing Lactobacillus acidophilus on diet- induced hypercholesterolemia in Wistar rats”. 13. Mohania D and Kansal VK. 2009. Presented a research paper in 101st Genenal meeting (American Society for Microbiology ASM),17th--21st May, 2009; Pennsylvania Convention Center, Philadelphia, Pennsylvania, U.S.A entitled “Effect of Probiotic Dahi Containing Lactobacillus acidophilus and Lactobacillus plantarum in Hypercholesterolemic Rats”. 14. Mohania D and Kansal VK. 2008. Presented a research paper in International Probiotic Conference, Probiotics for the 3rd Millennium June 4 -7 2008 Hotel Bellevue High Tatras, Slovakia entitled “A Probiotic dahi containing Lactobacillus plantarum attenuates diet induced hyperpercholesterolemia and deposition of cholesterol and triacylglycerols in liver and aortic tissue of wistar rats. Book chapters:- 1. Mohania D, Chandel S, Kumar P, Verma V, Digvijay K, Tripathi D, Choudhury K, Mitten SK, Shah D. 2017. Ultraviolet Radiations: Skin Defense-Damage Mechanism. Adv Exp Med Biol. 2017;996:71-87. doi: 10.1007/978-3-319-56017-5_7. 2. Mahajan N, Nath SK, Shah D, Mohania D, Nath S. 2015.''Crosstalk Between Oxidative Stress, Autophagy and Cell Death: pathogenesis of Autoimmune Disease''. Autoimmune Diseases, InTech Publications, ISBN 978-953-51-4188-4. 3. Mohania D, Jauhri M, Aggarwal S, Kansal VK, Ganguly NK, Choudhury S, Mohania S, Jain K 2014. Immuno-modulatory attributes of probiotics. In: Nagpal R, Kumar A and Singh R (Eds.) Microbes in the Service of Mankind: Tiny Bugs with Huge Impact. JBC Press, New Delhi, India (ISBN: 978-93-81558-85-0) pp. 864-907. 4. Mohania D, Kansal VK 2014. Probiotics in the prevention of breast cancer. In : Nagpal R, Kumar A and Singh R (Eds.) Microbes in the Service of Mankind: Tiny Bugs with Huge Impact. JBC Press, New Delhi, India (ISBN: 978-93-81558-85-0) pp. 922-936. 5. Menon S, Jain S, Nagpal R, Kumar M, Mohania D, Yadav D, Marotta F, Yadav M and Yadav H.2010. Immunomodulatory potential of conjugated linolenic acid in Dietary Componants and Immune function: Series: Nutrition and Health, Watson, Ronald Ross; Zibadi, Sherma;


Preedy, Victor, R. (Eds.), Ist Edition. 2010 Humana Press (Springer) ISBN: 978-1-60761-060-1. 6. Kumar M, Nagpal R, Mohania D, Yadav H and Verma V. 2009. Real-time PCR as an emerging tool for rapid detection of foodborne pathogens. In: edited by R Z Sayyed and A S Patil, Scientific publisher, Jodhpur, India, 267-280. 7. Verma V, Gautam S.K, Kumar M, Mohania D. and Chauhan M.S. 2006. “Framing the Future: Trangenic Technology, The Emerging Era Of Biotechnology, Biotechnology in Plant Improvement.

CURRICULUM VITAE DR. DHEERAJ MOHANIA, Ph.D. Tel ......2018/03/16 · Dr. Dheeraj Mohania,...

Documents

Transcript of CURRICULUM VITAE DR. DHEERAJ MOHANIA, Ph.D. Tel ......2018/03/16 · Dr. Dheeraj Mohania,...